Cancer Immunology Community Seeks Better End Points
November 29, 2016
Drug developers are still hunting for surrogate end points that can better capture the benefits of checkpoint inhibitors, oncolytic viruses and modified T cell therapies.
Continue reading here.
The detailed scans could inspire robots and biomechanical designs.
But the rise of robots and AI may disrupt the sport’s ethos.